beta-alanine has been researched along with Dyspepsia in 2 studies
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients given dabigatran for atrial fibrillation, NB-UGI AEs are generally mild or moderate; 4% stopped taking the drug over a median of 21." | 5.17 | Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. ( Aisenberg, J; Bytzer, P; Connolly, SJ; Ezekowitz, M; Formella, S; Reilly, PA; Yang, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schulman, S | 1 |
| Shortt, B | 1 |
| Robinson, M | 1 |
| Eikelboom, JW | 1 |
| Bytzer, P | 1 |
| Connolly, SJ | 1 |
| Yang, S | 1 |
| Ezekowitz, M | 1 |
| Formella, S | 1 |
| Reilly, PA | 1 |
| Aisenberg, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)[NCT03515083] | 100 participants (Actual) | Interventional | 2017-07-17 | Completed | |||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
1 trial available for beta-alanine and Dyspepsia
| Article | Year |
|---|---|
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da | 2013 |
1 other study available for beta-alanine and Dyspepsia
| Article | Year |
|---|---|
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; b | 2013 |